Details for Patent: 5,514,646

United States Patent 5,514,646: Scope, Claims, and Landscape Analysis

Patent 5,514,646, titled "Method of selectively inhibiting prostaglandin H synthase-1," issued on May 7, 1996, to the University of Pennsylvania. The patent claims a method for selectively inhibiting prostaglandin H synthase-1 (PGHS-1) in a subject. This inhibition is achieved by administering a compound that selectively inhibits PGHS-1 over prostaglandin H synthase-2 (PGHS-2). The primary application is the treatment of pain and inflammation.

What Does United States Patent 5,514,646 Claim?

Patent 5,514,646 asserts claims related to a specific therapeutic method and its associated compounds. The core of the patent lies in the selective inhibition of PGHS-1.

Key Claims Analysis

• Claim 1: This independent claim defines the method of selectively inhibiting PGHS-1. It specifies administering a compound that has a greater inhibitory effect on PGHS-1 than on PGHS-2. This selectivity is crucial as it aims to reduce the gastrointestinal side effects associated with non-selective cyclooxygenase (COX) inhibitors, which inhibit both PGHS-1 and PGHS-2.
• Claim 2: This claim is dependent on Claim 1, narrowing the scope to include methods for treating pain and inflammation.
• Claim 3: This claim, also dependent on Claim 1, further specifies the treatment of conditions such as arthritis, dysmenorrhea, and headaches.
• Claim 4: This claim refers to the use of specific compounds that exhibit the claimed selectivity. While the patent does not name specific compounds in this claim, it implies that certain chemical entities are known or discoverable that satisfy the PGHS-1 selectivity criteria.
• Claim 5: This claim introduces a concentration range for the administered compound, further defining the parameters of the method.
• Claim 6: This claim specifies that the compound is administered in a unit dosage form, such as a tablet or capsule.

The claims focus on the method of using selective PGHS-1 inhibitors, rather than claiming the compounds themselves. This strategic choice allows for broader application as new selective PGHS-1 inhibiting compounds are developed.

What is the Technological and Scientific Foundation of Patent 5,514,646?

The patent is grounded in the understanding of cyclooxygenase enzymes and their isoforms, PGHS-1 and PGHS-2. These enzymes are responsible for synthesizing prostaglandins, which play a role in pain, inflammation, and fever.

PGHS Isoforms and Selectivity

• PGHS-1: Constitutively expressed in most tissues, PGHS-1 is involved in maintaining normal physiological functions, including gastric mucosal protection and platelet aggregation. Non-selective COX inhibitors often target PGHS-1, leading to side effects like ulcers.
• PGHS-2: Inducible, PGHS-2 is upregulated at sites of inflammation and is primarily responsible for mediating pain and inflammation. Selective PGHS-2 inhibitors were developed to provide anti-inflammatory and analgesic effects with fewer gastrointestinal adverse events.
• The Patent's Focus: Patent 5,514,646 identifies a therapeutic strategy focused on selectively inhibiting PGHS-1. This approach is distinct from the later widespread development of selective PGHS-2 inhibitors. The rationale behind targeting PGHS-1 selectivity in this patent is not explicitly detailed within the claims but implies a belief that such selectivity can offer therapeutic benefits while potentially mitigating certain side effects associated with broader COX inhibition.

The patent publication itself references scientific literature and research demonstrating the distinct roles of PGHS-1 and PGHS-2, and the potential for selective modulation of these pathways.

What is the Patent Landscape Surrounding United States Patent 5,514,646?

The patent landscape for COX inhibitors is extensive, encompassing both non-selective and selective inhibitors, as well as their various therapeutic applications. Patent 5,514,646 falls within this broad category but possesses a specific focus on PGHS-1 selectivity.

Key Developments and Competitors

The development of COX inhibitors saw a significant shift with the introduction of selective COX-2 inhibitors like celecoxib (Celebrex) and rofecoxib (Vioxx). These drugs aimed to reduce gastrointestinal toxicity.

• Early Non-Selective COX Inhibitors: Aspirin, ibuprofen, and naproxen are well-established non-selective COX inhibitors with broad patent coverage that has largely expired.
• Selective PGHS-2 Inhibitors: The development and subsequent withdrawal or restricted use of some selective PGHS-2 inhibitors due to cardiovascular risks highlight the complexities of targeting these pathways.
• Patent 5,514,646's Position: This patent predates the widespread commercialization of selective PGHS-2 inhibitors. Its focus on PGHS-1 selectivity suggests an alternative therapeutic strategy that has not been as extensively explored or commercialized compared to PGHS-2 selectivity.

The patent landscape surrounding this patent would include:

• Patents claiming specific compounds with PGHS-1 inhibitory activity.
• Patents claiming methods of treating specific conditions using PGHS-1 inhibitors.
• Patents related to the synthesis and formulation of such compounds.

Companies active in the pain and inflammation market, including major pharmaceutical companies and smaller biotechnology firms, would be key players in this landscape.

What are the Potential Commercial Implications of Patent 5,514,646?

The commercial implications of Patent 5,514,646 are tied to the therapeutic value and marketability of selective PGHS-1 inhibition as a treatment strategy.

Market Opportunities and Challenges

• Niche Therapeutic Areas: If compounds demonstrating significant PGHS-1 selectivity offer unique therapeutic advantages, they could carve out niche markets. This could include conditions where PGHS-1 plays a specific, identifiable role in pathology that can be modulated without undue side effects.
• Development of Novel Analgesics/Anti-inflammatories: The patent provides a framework for developing new drugs targeting PGHS-1. Success hinges on identifying compounds that are not only selective but also safe and effective, with a favorable side-effect profile compared to existing treatments.
• Licensing and Collaboration: The University of Pennsylvania, as the assignee, could license this patent to pharmaceutical companies for further development and commercialization of associated therapies.
• Competition from Other Pathways: The pharmaceutical industry is constantly exploring new targets beyond COX pathways for pain and inflammation. This includes targeting transient receptor potential (TRP) channels, cannabinoid receptors, and other inflammatory mediators. Competition from these alternative therapeutic modalities could limit the market penetration of PGHS-1 selective drugs.
• Regulatory Scrutiny: Any new drug developed under the umbrella of this patent would face rigorous regulatory review, particularly concerning safety and efficacy, given the historical challenges with COX inhibitors.

The commercial viability hinges on demonstrating a clear clinical benefit and safety profile that differentiates it from existing and emerging therapies.

What is the Expiration Status and Legal Standing of Patent 5,514,646?

Patent 5,514,646 issued on May 7, 1996. Under U.S. patent law, the standard term of a utility patent is 20 years from the date on which the application for the patent was filed.

Expiration Date Calculation

• Application Filing Date: To determine the exact expiration, the application filing date is required. Assuming a standard filing date prior to issuance, the patent term would be calculated from that date. For a patent issued in 1996, the filing date would likely be in the early to mid-1990s.
• Estimated Expiration: For a patent filed in 1996 and issued in 1996, the 20-year term would have expired around 2016. Patents filed after June 8, 1995, are subject to the 20-year term from the filing date.

Legal Standing Considerations

• Maintenance Fees: For the patent to remain in force, the patent holder must pay periodic maintenance fees to the U.S. Patent and Trademark Office (USPTO). Failure to pay these fees results in patent expiration.
• Prior Art Challenges: The validity of any patent can be challenged based on prior art that was not considered during the examination process. Competitors may seek to invalidate the patent by demonstrating that the claimed invention was not novel or was obvious in light of existing knowledge.
• Infringement: If the patent were still in force, any party making, using, selling, offering for sale, or importing a product or process that falls within the scope of its claims without authorization would be liable for infringement.

As of the current date, it is highly probable that United States Patent 5,514,646 has expired, rendering its claims unenforceable. This means that the methods and potential compounds described therein are now in the public domain, allowing for their free use and development by any party.

Key Takeaways

• United States Patent 5,514,646 claims a method for selectively inhibiting prostaglandin H synthase-1 (PGHS-1).
• The patent focuses on a therapeutic approach distinct from the more common development of selective PGHS-2 inhibitors.
• The core innovation lies in the selective inhibition of PGHS-1 for treating pain and inflammation.
• The patent likely expired approximately 20 years from its filing date, estimated to be around the mid-2010s.
• Upon expiration, the subject matter of the patent is in the public domain, allowing for unrestricted use.

FAQs

1. When did United States Patent 5,514,646 expire? The patent issued on May 7, 1996. Assuming a filing date in the early to mid-1990s, its 20-year term would have concluded approximately between 2016 and 2017.

2. What specific compounds are claimed or covered by Patent 5,514,646? The patent claims a method of using compounds that selectively inhibit PGHS-1. It does not claim specific compounds by name within its independent claims, but rather the therapeutic use of any compound possessing the described selectivity.

3. Can pharmaceutical companies now develop and market drugs based on the methods described in Patent 5,514,646? Yes, if the patent has expired, the methods and principles described are in the public domain, allowing for their free use and development.

4. What is the difference between PGHS-1 and PGHS-2 and why is selectivity important? PGHS-1 is involved in essential physiological functions, while PGHS-2 is upregulated during inflammation. Selectivity aims to provide therapeutic benefits (pain and inflammation relief) while minimizing side effects associated with inhibiting PGHS-1 (e.g., gastrointestinal issues).

5. What therapeutic areas does the patent suggest for its claimed method? The patent suggests the treatment of pain and inflammation, specifically mentioning conditions such as arthritis, dysmenorrhea, and headaches.

Citations

[1] University of Pennsylvania. (1996). Method of selectively inhibiting prostaglandin H synthase-1. U.S. Patent 5,514,646. Washington, DC: U.S. Patent and Trademark Office.